A key issue will be the extent to which Nrf2 status influences HDAC levels and p16 expression at different stages of human colon cancer development and the ultimate response to pan-HDAC or HDAC-selective inhibitors. The gene discussed is HDAC9; the disease is malignant colon neoplasm.